High Dose BAYA1040 CR: a Long Term Extension Study
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This is a clinical study evaluating the safety and efficacy of long term administration of
oral BAYA1040 CR 80 mg/day (40 mg twice daily) in patients with essential hypertension for
whom the test drug is tolerable during the 8 week double blind treatment phase of Study
13176.